Article info

Download PDFPDF

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Authors

  • Matteo Lambertini Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, ItalyDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy PubMed articlesGoogle scholar articles
  • Matthias Preusser Clinical Divison of Oncology, Department of Medicine I, General Hospital – Medical University Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Christoph C Zielinski Vienna Cancer Center, City of Vienna - Medical University Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Matteo Lambertini; matteo.lambertini{at}unige.it
View Full Text

Citation

Lambertini M, Preusser M, Zielinski CC
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Publication history

  • Received February 11, 2019
  • Accepted March 11, 2019
  • First published June 12, 2019.
Online issue publication 
June 12, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.